Locally Advanced Pancreatic Cancer Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Current Locally Advanced Pancreatic Cancer Market Size and Its Estimated Growth Rate?
In recent times, the market size for locally advanced pancreatic cancer has seen a substantial increase. From 2024 to 2025, the market is set to rise from $0.95 billion to $1.05 billion, signifying a compound annual growth rate (CAGR) of 10.9%. This surge in the historic period can be credited to several factors such as enhanced awareness about pancreatic cancer, betterment in chemotherapy procedures, increased utilization of targeted therapies, a rise in pancreatic cancer cases, development of combined treatment protocols, and improved supportive care options.

The market size for locally advanced pancreatic cancer is anticipated to experience swift expansion in the subsequent years, achieving a value of $1.57 billion in 2029, signaling a compound annual growth rate (CAGR) of 10.5%. The acceleration in the projected timeline could be linked to the escalation in pancreatic cancer recognition, refined chemotherapy methods, increased application of targeted treatment options, rising occurrences of pancreatic cancer, evolution of mixed treatment methodologies, and improved options for supportive care. Key trends for the predicted time span include progress in immunotherapy, introduction of targeted methods, upgraded accuracy in radiation techniques, enhanced diagnostic imaging, introduction of less invasive surgical procedures, incorporation of artificial intelligence in treatment strategy formulation, and progression in mixed therapy.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214

How Are Emerging Segments Shaping the Locally Advanced Pancreatic Cancer Market Landscape?
The locally advanced pancreatic cancer market covered in this report is segmented -

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Surgery
2) By Route Of Administration: Oral, Injectables, Other Route Of Administrations
3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy
2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
3) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)
4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure), Distal Pancreatectomy, Total Pancreatectomy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

Which Growth Factors Are Influencing Locally Advanced Pancreatic Cancer Market Expansion?
The surge in tobacco use is predicted to accelerate the expansion of the local advanced pancreatic cancer markets. Derived from a plant, tobacco leaves are utilized in the production of items like cigarettes and cigars, delivering the addictive substance nicotine associated with severe health complications, including cancer and cardiovascular diseases. The escalation in tobacco usage is fueled by factors such as easy availability, cost-effectiveness, promotional activities surrounding tobacco, societal approval in some regions, and stress-induced smoking habits. The consumption of tobacco significantly contributes to the rise of local advanced pancreatic cancer by exacerbating the frequency of pancreatic tumors. Illustrating this, in January 2024, data from the U.S.-based non-profit organization Global Action to End Smoking revealed that in 2022, approximately 62.9 million U.S. adults consumed tobacco, placing it 4th worldwide and topping the list in the Americas. Furthermore, roughly 11.5% of U.S. adults (totalling 28.3 million) were cigarette smokers, with men (13.1%) having a higher incidence rate than women (10.1%). Thus, the surge in tobacco use is powering the expansion of the local advanced pancreatic cancer market.

Who Are the Dominant Players Across Different Locally Advanced Pancreatic Cancer Market Segments?
Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co

What Trends Are Driving Growth in The Locally Advanced Pancreatic Cancer Market?
Top corporations involved in the locally advanced pancreatic cancer market are focusing their efforts on creating innovative offerings, including orphan drugs. These efforts aim to widen treatment methods, enhance patient results, and cater to unresolved medical requirements related to this formidable illness. Tax cuts and exclusive market access are some incentives offered by regulatory authorities to encourage orphan drug development, catering to a smaller population with rare diseases. In January 2025 as an example, Actuate Therapeutics Inc., an American biopharmaceutical corporation, was granted Orphan Drug Designation by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Elraglusib. Elraglusib, being a novel GSK-3β inhibitor, is aimed at treating pancreatic ductal adenocarcinoma (PDAC), which is a possible variation of locally advanced pancreatic cancer. The granting of this status puts the spotlight on its potential to address a crucial need in the treatment of this intense form of cancer, particularly in light of encouraging results from Phase 2 trials showing considerable clinical advancements and anti-tumor impacts on patients with metastatic PDAC.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

Which Geographic Regions Are Expected to Dominate the Locally Advanced Pancreatic Cancer Market in the Coming Years?
North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Locally Advanced Pancreatic Cancer Market?
2. What is the CAGR expected in the Locally Advanced Pancreatic Cancer Market?
3. What Are the Key Innovations Transforming the Locally Advanced Pancreatic Cancer Industry?
4. Which Region Is Leading the Locally Advanced Pancreatic Cancer Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.